AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Akeso Biopharma announces first patient enrollment in Phase III AK112-309 trial for biliary tract tumor, comparing ivonescimab with durvalumab. The study aims to improve overall survival in advanced biliary tract cancers, following positive Phase II results showing significant antitumor activity and safety.

Akeso Biopharma announces first patient enrollment in Phase 3 trial of ivonescimab combination for biliary tract tumors, comparing it to durvalumab. The trial aims to establish ivonescimab as a first-line therapy, with overall survival as the primary endpoint.

Akeso Biopharma announces first patient enrollment in Phase 3 trial of ivonescimab combination for first-line therapy in biliary tract tumors, comparing it to durvalumab.

FDA approved Scemblix for newly diagnosed chronic myeloid leukemia, based on ASC4FIRST trial showing 68% major molecular response rate at 48 weeks vs. 49% with tyrosine kinase inhibitors. Common side effects include rash, musculoskeletal pain, and upper respiratory tract infection.

Emerging therapies for bladder cancer include erdafitinib, enfortumab vedotin, and pembrolizumab. Key studies highlight genomic heterogeneity, biomarker guidance, and immunotherapy responses. Precision oncology faces challenges with clonal evolution and resistance mechanisms. Future directions focus on improving biomarker-driven trials and understanding tumor immune microenvironments.

ctDNA shows potential to predict colon cancer recurrence, aiding in precision medicine by identifying genetic markers for treatment decisions. Studies like BESPOKE CRC and CIRCULATE-NORTH AMERICA explore ctDNA's utility in adjuvant therapy, with ctDNA positivity linked to poorer outcomes. Ongoing research aims to integrate ctDNA into treatment strategies, avoiding overtreatment and developing new adjuvant therapies.

Investigators aim to improve rural cancer care access through decentralized clinical trials and better data sharing. Challenges include lack of specialized oncologists, infrastructure, and socioeconomic factors. Decentralized trials use online consent, home delivery, and mobile tech. COVID-19 pandemic accelerated decentralized trial use, increasing rural patient enrollment. The Catchment Area Research and Data Science (CARDS) group aims to streamline data collection and analysis for better care in underserved areas.

Recent clinical studies in renal cell carcinoma (RCC) show immunotherapy-based combination regimens offer personalized treatment options, with confirmed benefits of entrenched regimens. Data from trials like CheckMate 214, CheckMate 9ER, and CLEAR support FDA approvals for combinations including nivolumab plus ipilimumab, nivolumab plus cabozantinib, and pembrolizumab plus lenvatinib. Long-term follow-up data reveal significant improvements in overall survival and progression-free survival, with biomarker analyses indicating consistent benefits across various RCC subgroups. The evolving landscape also includes second-line treatments like atezolizumab plus cabozantinib and adjuvant pembrolizumab, as well as HIF2α inhibitors like belzutifan. Research in non–clear cell RCC highlights the potential of immunotherapy combinations, with ongoing studies like PAPMET2 and KEYNOTE-B61 exploring new treatment strategies.

Olanzapine significantly reduced severe nausea in breast cancer patients during chemotherapy, outperforming prochlorperazine. A cannabis extract also showed efficacy in relieving chemotherapy-induced nausea and vomiting, though with more side effects.

A decade-old program at UNC Lineberger Comprehensive Cancer Center has significantly increased assistance to AYAs with cancer, boosting fertility counseling, clinical trial enrollment, and guideline-recommended care. The program, inspired by a patient, aims to standardize its components for broader adoption by other cancer centers. Despite challenges, leveraging technology and nonprofit support is expanding access to AYA programs.